Skip to main content
Fig. 7 | Molecular Cancer

Fig. 7

From: The therapeutically actionable long non-coding RNA ‘T-RECS’ is essential to cancer cells’ survival in NRAS/MAPK-driven melanoma

Fig. 7

T-RECS ASO treatment significantly suppresses melanoma tumor growth in vivo. a) Significant tumor growth reduction was observed when comparing treatment groups for systemic (s.c.) treatment with either T-RECS ASO (red) or Control ASO (black) in mouse models carrying xenografts of the D04 melanoma cell line (3 × 200 µg ASO/week, n = 6). b-d) Significant tumor growth reduction was observed when comparing treatment groups for systemic (s.c.) treatment with either T-RECS ASO (red) or Control ASO (black) in mouse models carrying xenografts of the b) D04 melanoma cell line (n = 5), c) AV5 primary melanoma cell line (n = 3) or d) TM01341 (n = 4) PDX patient derived tumor model (2 × 60 µg ASO/week + in vivo transfection reagent jetPEI). e-h) The panels depict the progression of average mouse weight over time. Each panel corresponds to the weight trends of the treatment groups indicated above (a-d). No significant weight changes were observed between the T-RECS ASO and Control ASO groups at any time-point (p > 0.05). All growth and weight curves are presented as polynomial trend lines (Data for tumor sizes and weight over time are listed in Suppl. Table 6). i) T-RECS RNA levels were reduced in tumors of T-RECS ASO treatment groups compared Control ASO treatment groups at the end of study period of all cohorts shown in b-d). Tumours were harvested at end of treatment period and relative gene expression was normalized to Control ASO treated tumours. T-RECS RNA levels were reduced in D04 (0.25-fold, SD = 0.1), AV5 (0.44-fold) and PDX TM01341 tumours (0.34-fold). j) Immunohistochemical staining for the apoptosis marker Cleaved-Caspase-3 at the end of study period in tumors from Control ASO (left) or T-RECS ASO treatment (right) of treatment groups shown in panel b). k) Hematoxylin-eosin staining of mouse liver tissue after the end of the treatment period at the end of study period in tumors from Control ASO (left) or T-RECS ASO treatment (right) of treatment groups shown in panel b). Significance is shown as p-values calculated by Student’s t-test. * = p < 0.05, ** = p < 0.01, *** = p < 0.001

Back to article page